News Release

Cleanascite™ Employed to Investigate Lipid-enriched Microenvironment of Ovarian Cancer Cells

MONMOUTH JUNCTION, NJ , December 1, 2021 -- Biotech Support Group reports on an article, describing the simplicity and efficiency of their lipid clearance sample preparation technology for studying malignant ascites in peritoneal metastases of epithelial ovarian cancer . The citation is:

Yang, X. U. A. N., et al. " SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells ." (2021).

Malignant ascites in peritoneal metastases is a lipid-enriched microenvironment and is frequently involved in the poor prognosis of epithelial ovarian cancer (EOC). However, the detailed mechanisms underlying ovarian cancer (OvCa) cells dictating their lipid metabolic activities in promoting tumor progression remain elusive.

For this, the BSG product Cleanascite™ was used as a lipid-cleared control in the investigation. The article states: “Compared with the negative controls (OCM pretreated with the lipid removal reagent, Cleanascite), OvCa cells cocultured in the lipid-enriched OCM showed an increase of 18% in membrane fluidity.” The authors describe a disruption of the cellular redox balance and subsequent iron-mediated lipid peroxidation in ascites-derived OvCa cells. They conclude that combinational treatment with SCD1/FADS2 inhibitors and cisplatin synergistically repressed tumor cell dissemination, providing a promising chemotherapeutic strategy against EOC platinum resistance and peritoneal metastases.

“We have over twenty references showing that Cleanascite™ was used to help identify a characteristic feature of in vitro cell response. Unlike methods that use solvents, Cleanascite™ is an aqueous suspension product and so it is very compatible with cellular models of disease. This ultimately helps with investigations to determine whether or not lipids, or factors associated with lipids, impart phenotypic changes to cells.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

To download whitepaper entitled “ Cleanascite™ - Lipid Removal and Cell Response Applications ”, visit:

https://www.biotechsupportgroup.com/v/vspfiles/templates/257/pdf/CleanasciteCellResponseReferenceApplications113021.pdf

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com.

For Business Development , contact: Matthew Kuruc 732-274-2866 , mkuruc@biotechsupportgroup.com